Literature DB >> 19429178

CAT53 and HFE alleles in Alzheimer's disease: a putative protective role of the C282Y HFE mutation.

Ana Paula Correia1, Jorge P Pinto, Vera Dias, Cláudia Mascarenhas, Susana Almeida, Graça Porto.   

Abstract

Alzheimer's disease (AD) is a complex disorder, resulting from an interaction between environmental and genetic factors. Several studies addressed the association of AD with MHC class-I polymorphisms without definite conclusions. Considering the remarkable linkage disequilibrium at the MHC region, it is not possible to assume if the reported associations result from a direct effect of the respective genes or result from associations with other closely linked genes transmitted in an extended conserved haplotype. Recent evidence pointed to CAT53, a newly described gene located at the MHC class-I region in the vicinity of HLA-C, as a candidate modifier gene in AD. CAT53 encodes a phosphatase 1 nuclear inhibitor protein and is strongly expressed in brain regions involved in memory and AD. Here we tested the potential association of CAT53 with the risk of developing AD and searched for potential haplotypic associations of CAT53 with two common mutations (H63D, C282Y) in the HFE gene, also located at chromosome 6p21.3. The allele frequencies of these mutations in AD patients were compared to the expected frequencies previously established in the normal Portuguese population. We detected only one polymorphism (G>A) in CAT53, at position 8232, in intron 17. Screening of this polymorphism in 113 AD patients and 82 controls did not show any evidence of association, therefore excluding the hypothetical role of the CAT53 polymorphism as modifier in AD. In contrast, we found a significant negative association of the C282Y HFE mutation with AD, thus supporting a putative protective role of this protein variant in neurodegeneration.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19429178     DOI: 10.1016/j.neulet.2009.03.088

Source DB:  PubMed          Journal:  Neurosci Lett        ISSN: 0304-3940            Impact factor:   3.046


  6 in total

1.  Effect of HFE variants on sphingolipid expression by SH-SY5Y human neuroblastoma cells.

Authors:  F Ali-Rahmani; J A Hengst; J R Connor; C-L Schengrund
Journal:  Neurochem Res       Date:  2011-01-18       Impact factor: 3.996

2.  Association between HFE polymorphisms and susceptibility to Alzheimer's disease: a meta-analysis of 22 studies including 4,365 cases and 8,652 controls.

Authors:  Min Lin; Lin Zhao; Jin Fan; Xue-Gan Lian; Jian-Xin Ye; Lei Wu; Hang Lin
Journal:  Mol Biol Rep       Date:  2011-06-24       Impact factor: 2.316

3.  Alzheimer's disease and HLA-A2: linking neurodegenerative to immune processes through an in silico approach.

Authors:  Ricardo A Cifuentes; Juan Murillo-Rojas
Journal:  Biomed Res Int       Date:  2014-08-17       Impact factor: 3.411

Review 4.  Pathophysiological consequences and benefits of HFE mutations: 20 years of research.

Authors:  Ina Hollerer; André Bachmann; Martina U Muckenthaler
Journal:  Haematologica       Date:  2017-03-09       Impact factor: 9.941

5.  Gene-gene interactions among coding genes of iron-homeostasis proteins and APOE-alleles in cognitive impairment diseases.

Authors:  Veronica Tisato; Giovanni Zuliani; Marco Vigliano; Giovanna Longo; Eugenia Franchini; Paola Secchiero; Giorgio Zauli; Elvezia Maria Paraboschi; Ajay Vikram Singh; Maria Luisa Serino; Beatrice Ortolani; Amedeo Zurlo; Cristina Bosi; Antonio Greco; Davide Seripa; Rosanna Asselta; Donato Gemmati
Journal:  PLoS One       Date:  2018-03-08       Impact factor: 3.240

Review 6.  HFE gene variants, iron, and lipids: a novel connection in Alzheimer's disease.

Authors:  Fatima Ali-Rahmani; Cara-Lynne Schengrund; James R Connor
Journal:  Front Pharmacol       Date:  2014-07-08       Impact factor: 5.810

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.